Genopore

Executive Summary

Genopore is an Israeli biotech company pioneering a novel digital proteomics platform that replaces traditional mass spectrometry with a combination of chemo-selective labeling, solid-state nanopore translocation, and AI-driven optical readout. This approach enables single-molecule protein identification and quantification, offering potential breakthroughs in diagnostics, drug discovery, and precision medicine. Founded in 2020, the company has raised $150 million to date, reflecting strong investor confidence in its technology. Genopore's platform aims to address key limitations of existing proteomic methods, such as high cost, complexity, and low throughput, by providing a scalable, real-time solution for protein analysis at the molecular level. With a team of 50-200 employees based in Rehovot, Israel, Genopore is positioned at the forefront of next-generation proteomics. The company's stage as a platform developer suggests a focus on technology maturation and commercialization rather than specific product launches. Given its substantial funding and innovative approach, Genopore is likely to attract further investment and partnerships. Key upcoming catalysts include progress towards a commercial product, possibly in the diagnostic or drug discovery sectors, and strategic collaborations with pharmaceutical or biotech firms. The company's success will depend on demonstrating the platform's reliability and superiority over existing methods, which could significantly impact the field of proteomics.

Upcoming Catalysts (preview)

• Q2 2027Next financing round (Series C or D) to support commercialization80% success
• Q4 2026First commercial product launch or beta release of the proteomics platform60% success
• Q3 2026Strategic partnership with a major pharmaceutical or diagnostic company70% success